Compare HSAI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HSAI | AGIO |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2021 | 2013 |
| Metric | HSAI | AGIO |
|---|---|---|
| Price | $14.36 | $31.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 10 |
| Target Price | $23.18 | ★ $46.11 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $25.38 | $227.92 |
| Revenue Next Year | $38.59 | $96.10 |
| P/E Ratio | $61.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.00 | $22.24 |
| 52 Week High | $29.35 | $46.00 |
| Indicator | HSAI | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 46.33 |
| Support Level | $14.34 | $31.25 |
| Resistance Level | $19.29 | $35.77 |
| Average True Range (ATR) | 0.61 | 1.86 |
| MACD | 0.30 | -0.17 |
| Stochastic Oscillator | 74.21 | 36.18 |
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.